Repositorio UFRO · Omeka S

Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment

Primer Autor	Paz, Cristian
Co-autores	Perez, Rebeca Glaser, Talita Villegas, Cecilia Burgos, Viviana Ulrich, Henning
Título	Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment
Editorial	MDPI
Revista	LIFE-BASEL
Lenguaje	en
Resumen	Cannabis sativa is one of the first medicinal plants used by humans. Its medical use remains controversial because it is a psychotropic drug whose use has been banned. Recently, however, some countries have approved its use, including for recreational and medical purposes, and have allowed the scientific study of its compounds. Cannabis is characterized by the production of special types of natural products called phytocannabinoids that are synthesized exclusively by this genus. Phytocannabinoids and endocannabinoids are chemically different, but both pharmacologically modulate CB1, CB2, GRP55, GRP119 and TRPV1 receptor activities, involving activities such as memory, sleep, mood, appetite and motor regulation, pain sensation, neuroinflammation, neurogenesis and apoptosis. Delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are phytocannabinoids with greater pharmacological potential, including anti-inflammatory, neuroprotective and anticonvulsant activities. Cannabidiol is showing promising results for the treatment of COVID-19, due to its capability of acting on the unleashed cytokine storm, on the proteins necessary for both virus entry and replication and on the neurological consequences of patients who have been infected by the virus. Here, we summarize the latest knowledge regarding the advantages of using cannabinoids in the treatment of COVID-19.
Fecha Publicación	2022
Tipo de Recurso	artículo de revisión
doi	10.3390/life12122117
Formato Recurso	PDF
Palabras Claves	refractory epilepsy COVID-19 phytocannabinoids synthetic cannabinoids clinical trials
Ubicación del archivo	http://dx.doi.org/10.3390/life12122117
Categoría OCDE	Ciencias biológicas y biomedicina: otros temas Microbiología Biotecnología Médica Farmacología y Farmacia
Materias	epilepsia refractaria COVID-19 fitocannabinoides cannabinoides sintéticos ensayos clínicos
Identificador del recurso (Mandatado-único)	artículo de revisión
Versión del recurso (Recomendado-único)	versión publicada
License	CC BY 4.0
Condición de la licencia (Recomendado-repetible)	CC BY 4.0
Derechos de acceso	acceso abierto
Access Rights	acceso abierto
Id de Web of Science	WOS:000902365700001
Tipo de ruta	verde# dorado
Categoría WOS	Ciencias biológicas y biomedicina: otros temas Microbiología
Referencia del Financiador (Mandatado si es aplicable-repetible)	FAPESP 2018/07366-4 ANID 201808426-0 CNPq 406396/2021-3 USP-PIPAE